• Interestingly from our consensus SBVC protocol

  2020-10-16

  

  Interestingly, from our consensus SBVC protocol only few compounds (less than 150) have been scored with a full ‘ consensus’. That means that these compounds appear in the top 5% of the database when ranked by every scoring function independently. After visual inspection, we have realized that two a

• Several of the plant extracts that showed interaction with E

  2020-10-16

  

  Several of the plant extracts that showed interaction with ERα and ERβ have differing reports concerning estrogenicity and receptor binding. Extracts of dong quai stimulated MCF-7 proliferation but failed to increase uterine weight or transactivate either ERα or ERβ in a cell assay (Amato et al., 20

• In our former work our interest was in discovery of

  2020-10-16

  

  In our former work, our interest was in discovery of novel VEGFR-2 inhibitors as anti-angiogenesis agents. Along this line, with natural alkaloid taspine as the lead compound, rounds of structure optimization were performed to develop novel VEGFR-2 inhibitors [[13], [14], [15]]. Among them, BPS-7, b

• In order to evaluate the in vivo pharmacology

  2020-10-16

  

  In order to evaluate the in vivo pharmacology associated with EP receptor antagonism, we wished to discover antagonists presenting a higher degree of selectivity over the other prostanoid receptors. We also wanted to increase the brain–blood ratio since it is probable that centrally mediated EP agon

• br Experimental br Results and discussion

  2020-10-16

  

  Experimental Results and discussion Conclusion Acknowledgements This work was funded by the National Natural Science Foundation of China (81572080, 81873972and81873980), the National Science and Technology Major Project of the Ministry of Science and Technology of China (2018ZX10732202),

• br O GlcNAcase Human OGA is a multidomain

  2020-10-16

  

  O-GlcNAcase Human OGA is a multidomain protein with an N-terminal domain similar to glycoside hydrolase family 84 (GH84) enzymes, a stalk domain, a C-terminal pseudo histone acetyltransferase (HAT) domain, and several low-complexity regions (Figure 1f) [43]. A splice variant that lacks the HAT do

• br O GlcNAcase Human OGA

  2020-10-16

  

  O-GlcNAcase Human OGA is a multidomain protein with an N-terminal domain similar to glycoside hydrolase family 84 (GH84) enzymes, a stalk domain, a C-terminal pseudo histone acetyltransferase (HAT) domain, and several low-complexity regions (Figure 1f) [43]. A splice variant that lacks the HAT do

• Three kinase inhibitors dasatinib type I

  2020-10-16

  

  Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors

• Circulating NK subsets also show considerable differences in

  2020-10-16

  

  Circulating NK subsets also show considerable differences in homing molecules. CD56bright PRT 4165 receptor express the chemokine receptor CCR7 and L-selectin, which drive their migration to secondary lymphoid organs (Fehniger et al., 2003). In contrast, CD56dim display a high density of CX3CR1 and

• Inflammation is critical in the pathobiology of

  2020-10-16

  

  Inflammation is critical in the pathobiology of atherosclerosis. The inflammatory mediators impacted by FBXO3 described herein i.e. NF-κB, IL-1β, and TNF-α, and IL-8 have purported causal roles in atherosclerosis. For example, NF-κB activation is increased in mononuclear cells in human plaques [29]

• br RING type E s and their substrates There

  2020-10-15

  

  RING-type E3s and their substrates There is enormous diversity in substrate ubiquitination and its regulation, as the targets of RING-type E3s are incredibly varied. RING-type E3s are implicated as tumor suppressors, oncogenes, and mediators of endocytosis, and play critical roles in complex mult

• Our finding that activating DDR variants

  2020-10-15

  

  Our finding that activating DDR2 variants are a cause of this disease suggested that the ABL inhibitor dasatinib, a leukemia drug that also inhibits DDR2, could be used for treatment of affected individuals.10, 11 To examine the effect of dasatinib on p.Leu610Pro- and p.Tyr740Cys-induced autophospho

• In conclusion our data demonstrated that montelukast

  2020-10-15

  

  In conclusion, our data demonstrated that montelukast and pranlukast non-competitively blocked P2Y signaling in several cell systems, but in a relatively nonsubtype-specific manner. The functional antagonism was especially evident at heterologously expressed P2Y1 and P2Y6 receptors, at which IC50 va

• As described above we designed and synthesized a new

  2020-10-14

  

  As described above, we designed and synthesized a new 1,4-di-substituted isoquinoline lead compound, and was identified as a ligand with moderate potency for the CRTH2 receptor. We initially we examined the effects of the steric factor of R group on the CRTH2 binding potency (). When the methyl gro

• Numerous small molecule CRF receptor antagonists have been r

  2020-10-14

  

  Numerous small molecule CRF receptor antagonists have been reported in the literature. Some representative examples are shown in . In preclinical studies (DMP696), , was found to be efficacious in preclinical behavioral models for anxiety and depression. In an open label clinical trial with (R121

15674 records 767/1045 page Previous Next First page 上5页 766767768769770 下5页 Last page